Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More
Xconomy
AUGUST 5, 2016
Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. —Immunotherapy news: Menlo Park, CA-based Adicet Bio struck a five-year deal with Regeneron Pharmaceuticals (NASDAQ: REGN ) to make “off the shelf” T cell treatments for various cancers.
Let's personalize your content